Safety of low volume iodinated contrast administration for arteriovenous fistula intervention in chronic kidney disease stage 4 or 5 utilizing a bicarbonate prophylaxis strategy

Semin Dial. 2010 Nov-Dec;23(6):638-42. doi: 10.1111/j.1525-139X.2010.00800.x.

Abstract

Efforts to increase the number of functioning arteriovenous fistulas in chronic kidney disease (CKD) stages 4 and 5 have been impacted by concerns about the risk for contrast-induced nephropathy during diagnostic and interventional procedures for poorly developed fistulas. We conducted a prospective observational study of low volume iodinated contrast administration for fistulography and angioplasty in a CKD stage 4 and stage 5 population pretreated with a sodium bicarbonate protocol. Acute kidney injury was assessed by change in serum creatinine and urinary neutrophil-gelatinase associated lipocalcin (NGAL). Only 1/18 patients (5.5%) developed acute kidney injury as defined by change in serum creatinine 48 hours after contrast exposure. No patients demonstrated significant change in urinary NGAL at 3 or 48 hours after procedure, nor did any require acute initiation of dialysis. Fistulography alone, or with angioplasty, utilizing a low volume of iodinated contrast and sodium bicarbonate solution for prophylaxis, appears to be safe in the CKD stages 4 and 5 population.

Publication types

  • Comparative Study

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / prevention & control*
  • Acute Kidney Injury / urine
  • Aged
  • Arteriovenous Shunt, Surgical / methods*
  • Bicarbonates / therapeutic use*
  • Contrast Media / administration & dosage*
  • Contrast Media / adverse effects
  • Contrast Media / pharmacokinetics
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Intravenous
  • Kidney Failure, Chronic / diagnostic imaging
  • Kidney Failure, Chronic / therapy*
  • Kidney Failure, Chronic / urine
  • Male
  • Prognosis
  • Prospective Studies
  • Radiography
  • Renal Dialysis / methods*
  • Severity of Illness Index
  • Triiodobenzoic Acids / administration & dosage*
  • Triiodobenzoic Acids / adverse effects
  • Triiodobenzoic Acids / pharmacokinetics

Substances

  • Bicarbonates
  • Contrast Media
  • Triiodobenzoic Acids
  • ioversol